Cochlear Ltd (ASX: COH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Cochlear Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $21.02 billion
P/E Ratio 59.95
Dividend Yield 1.18%
Shares Outstanding 65.49 million
Earnings per share 5.321
Dividend per share 4.00
Year To Date Return 7.48%
Earnings Yield 1.67%
Franking 70
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Cochlear Ltd (ASX: COH)
    Latest News

    Close up portrait of happy businesswoman standing in front or leading her multi-ethnic corporate team.
    Dividend Investing

    6 ASX 200 shares with ex-dividend dates next week

    There are six ASX 200 shares that will cut off dividend eligibility next week.

    Read more »

    Young businesswoman sitting in kitchen and working on laptop.
    Broker Notes

    3 no-brainer ASX shares to buy under $30

    Analysts think these shares are top buys for investors right now.

    Read more »

    sad party goer sitting alone after celebration
    Share Market News

    Here are the top 10 ASX 200 shares today

    It was a tough Wednesday for ASX 200 shares today.

    Read more »

    A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
    Broker Notes

    How these 4 ASX 200 shares just gained major broker upgrades

    Brokers are forecasting substantial 2024 share price gains from these four ASX 200 shares.

    Read more »

    Man holding out Australian dollar notes, symbolising dividends.
    Dividend Investing

    Everything you need to know about the record Cochlear dividend

    The latest Cochlear dividend will disappoint no one.

    Read more »

    Young girl shows hearing aid while smiling
    Earnings Results

    Cochlear share price falls despite 29% dividend boost

    Cochlear has reported some big numbers today.

    Read more »

    A piggy bank on the cloud in the blue sky symbolising a record high share price.
    52-Week Highs

    Big news: 15 ASX 200 shares smashing 52-week highs this Tuesday

    52-week highs are falling like flies on the ASX 200 today.

    Read more »

    Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
    Share Market News

    Here's how the ASX 200 market sectors stacked up this week

    The ASX 200 gained 0.36% in the first week of the earnings season, finishing at 7,644.8 points on Friday.

    Read more »

    People on a rollercoaster waving hands in the air, indicating a plummeting or rising share price
    Share Market News

    Here are the top 10 ASX 200 shares today

    The ASX 200 wrapped up the trading week with a rise today.

    Read more »

    A diverse group of people form a circle at a park and raise their arms together.
    Share Market News

    Here are the top 10 ASX 200 shares today

    Earnings reports helped boost the ASX 200 to another gain today.

    Read more »

    A young woman holding her phone smiles broadly and looks excited, after receiving good news.
    Share Gainers

    Why AGL, Cochlear, Mirvac, and News Corp shares are storming higher

    These ASX shares are having strong sessions. What's getting investors excited?

    Read more »

    Two colleagues at work looking at a tablet and smiling at a rising share price.
    Healthcare Shares

    Cochlear shares jump 6% on guidance upgrade

    Demand for Cochlear's products has been stronger than expected in FY 2024.

    Read more »

    Frequently Asked Questions

    Yes, Cochlear Ltd has historically paid two fully franked dividends a year. From October 2019, dividends were unfranked until October 2022 when dividends were 40% franked.

    Cochlear Ltd generally pays its dividends in April and October. 

    Cochlear Ltd listed on the ASX on 4 December 1995.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    21 Mar 2024 $2.0000 70.00% Interim 15 Apr 2024
    18 Sep 2023 $1.7500 70.00% Final 11 Oct 2023
    21 Mar 2023 $1.5500 35.00% Interim 14 Apr 2023
    21 Sep 2022 $1.4500 40.00% Final 17 Oct 2022
    28 Mar 2022 $1.5500 0.00% Interim 21 Apr 2022
    23 Sep 2021 $1.4000 0.00% Final 18 Oct 2021
    25 Mar 2021 $1.1500 0.00% Interim 20 Apr 2021
    19 Sep 2019 $1.7500 100.00% Final 14 Oct 2019
    25 Mar 2019 $1.5500 100.00% Interim 16 Apr 2019
    17 Sep 2018 $1.6000 100.00% Final 10 Oct 2018
    19 Mar 2018 $1.4000 100.00% Interim 12 Apr 2018
    19 Sep 2017 $1.0000 100.00% Final 11 Oct 2017
    15 Mar 2017 $1.3000 100.00% Interim 06 Apr 2017
    07 Sep 2016 $1.2000 100.00% Final 29 Sep 2016
    10 Mar 2016 $1.1000 100.00% Interim 01 Apr 2016
    02 Sep 2014 $1.2700 20.00% Final 25 Sep 2014
    20 Feb 2006 $0.4500 100.00% Interim 14 Mar 2006
    26 Aug 2005 $0.4500 100.00% Final 22 Sep 2005
    19 Feb 2004 $0.3500 100.00% Interim 17 Mar 2004

    COH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Cochlear Ltd

    Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.

    The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.

    Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.

    Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.

     

    COH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    11 Apr 2024 $321.00 $1.98 0.62% 130,945 $313.82 $321.00 $313.37
    10 Apr 2024 $319.02 $-0.05 -0.02% 240,422 $319.07 $324.40 $317.41
    09 Apr 2024 $319.07 $-6.96 -2.13% 107,265 $323.50 $326.02 $317.99
    08 Apr 2024 $326.03 $-0.40 -0.12% 85,858 $324.80 $329.44 $324.60
    05 Apr 2024 $326.43 $-7.16 -2.15% 99,109 $330.76 $331.80 $326.43
    04 Apr 2024 $333.59 $3.66 1.11% 92,515 $333.99 $336.28 $331.50
    03 Apr 2024 $329.93 $-6.19 -1.84% 109,049 $332.86 $335.07 $329.29
    02 Apr 2024 $336.12 $-1.40 -0.41% 139,973 $340.21 $342.40 $335.22
    28 Mar 2024 $337.52 $0.69 0.20% 122,848 $338.49 $340.15 $335.45
    27 Mar 2024 $336.83 $1.88 0.56% 74,044 $341.57 $341.57 $333.91
    26 Mar 2024 $334.95 $-2.36 -0.70% 114,213 $338.91 $339.25 $333.90
    25 Mar 2024 $337.31 $5.56 1.68% 96,366 $331.94 $338.23 $330.92
    22 Mar 2024 $331.75 $2.88 0.88% 80,017 $330.32 $331.75 $325.16
    21 Mar 2024 $328.87 $-0.81 -0.25% 229,602 $331.30 $333.60 $323.00
    20 Mar 2024 $329.68 $-0.31 -0.09% 256,069 $328.90 $330.85 $326.93
    19 Mar 2024 $329.99 $-2.71 -0.81% 121,661 $332.62 $333.50 $326.51
    18 Mar 2024 $332.70 $-0.28 -0.08% 76,214 $331.70 $333.31 $330.27
    15 Mar 2024 $332.98 $-3.54 -1.05% 270,676 $334.08 $334.82 $330.09
    14 Mar 2024 $336.52 $3.75 1.13% 150,183 $332.81 $337.38 $330.44
    13 Mar 2024 $332.77 $-0.99 -0.30% 158,738 $333.85 $334.36 $330.83

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    12 Mar 2024 Dig Howitt Exercise 279 $60,621
    Exercise of options.
    12 Mar 2024 Dig Howitt Buy 279 $60,621
    Exercise of options.
    14 Nov 2023 Michael del Prado Buy 117 $19,798
    On-market trade. USD$
    18 Oct 2023 Dig Howitt Issued 14,089 $3,599,739
    Issue of options.
    18 Oct 2023 Dig Howitt Issued 4,938 $1,261,659
    Issue of securities. 27,981 Performance Rights
    18 Oct 2023 Karen Penrose Buy 138 $34,886
    On-market trade.
    18 Sep 2023 Dig Howitt Issued 3,622 $936,431
    Issue of securities. 23,043 Performance Rights
    05 Sep 2023 Karen Penrose Buy 130 $34,806
    On-market trade.
    31 Aug 2023 Christine McLoughlin Buy 250 $67,805
    On-market trade.
    23 Aug 2023 Dig Howitt Sell 6,000 $1,589,760
    On-market trade.
    22 Aug 2023 Dig Howitt Exercise 6,000 $1,303,680
    Exercise of options.
    22 Aug 2023 Dig Howitt Buy 6,000 $1,303,680
    Exercise of options.
    18 Aug 2023 Michael del Prado Buy 147 $24,475
    On-market trade. USD$
    17 Aug 2023 Michael Daniell Buy 200 $49,382
    On-market trade.
    16 Aug 2023 Dig Howitt Exercise 1,157 $284,853
    Conversion of securities. 26,547 Rights
    16 Aug 2023 Dig Howitt Exercise 3,851 $948,116
    Conversion of securities. 22,696 Rights
    16 Aug 2023 Dig Howitt Expiry 3,275 $806,305
    As advised by the company. Forfeit 19,421 rights
    16 Aug 2023 Dig Howitt Expiry 17,762 $4,373,004
    Options expired.
    16 Aug 2023 Dig Howitt Buy 5,008 $1,232,969
    Conversion of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Christine Frances McLoughlin Non-Executive Director Nov 2020
    Mr Denver has experience in the life sciences industry. He is former Managing Director of Memtec Limited and President Asia for Pall Corporation.
    Mr Michael Grenfell Daniell Non-Executive Director Jan 2020
    Mr Daniell has over 40 years' experience in the medical device industry with executive leadership experience. Former Managing Director and CEO of Fisher & Paykel Healthcare Corporation Limited responsible for the global business and operations including the design, manufacture and marketing of innovative products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea.
    Ms Catriona Alison Deans Non-Executive DirectorNon-Executive Chairman Jan 2015
    Ms Deans has experience in technology-enabled businesses across e-commerce, media and financial services. She is former Chief Executive Officer of netus, Hoyts Cinemas, ecorp and eBay Australia and New Zealand.
    Ms Yasmin Anita Allen Non-Executive Director Aug 2010
    Ms Allen has career in investment banking with senior roles in strategic analysis and corporate advice. Former Vice President of Deutsche Bank AG, Director of ANZ Investment Bank and Associate Director of HSBC London.
    Ms Karen Lee Collett Penrose Non-Executive Director Jul 2022
    Ms Penrose has career in senior leadership and Chief Financial Officer roles in financial services. She served on the boards of a number of ASX100 companies and experienced across health care, financial services, property and infrastructure industries.
    Mr Glen Francis Boreham Non-Executive Director Jan 2015
    Mr Boreham led organisations in information technology, new media and the creative industries through periods of rapid change and innovation. Former Managing Director of IBM Australia and New Zealand. He is Director of Southern Cross Media Group and Link Group and Strategic Advisor of IXUP.
    Professor Bruce Gregory Robinson Non-Executive Director Dec 2016
    Prof Robinson have 20 years leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. Former Dean of The University of Sydney's Sydney Medical School, Head of Medicine at Sydney's Royal North Shore Hospital and Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research. Other boards includes Chairman, National Health and Medical Research Council. Director, MaynePharma, QBiotocs and Ecofibre. Director, Woolcock Institute of Medical Research and Senior Advisor to McKinsey & Company and MinterEllison.
    Mr Dig Howitt PresidentChief Executive OfficerManaging Director Jul 2017
    Mr Howitt has experience across the Company in roles including Chief Operating Officer, President, Asia Pacific and SVP, Manufacturing and Logistics. Dig worked for Boston Consulting Group and held a General Management role at Boral.
    Mr Michael del Prado Non-Executive Director Jan 2022
    Mr Prado has over 34 years' global experience in the medical device and pharmaceutical industries with senior executive leadership roles in Johnson & Johnson medical device businesses in the US, Asia-Pac and EMEA.
    Mr Ray Jarman Company Secretary Feb 2017
    -
    Ray Jarman Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 29,384,578 44.75%
    J P Morgan Nominees Australia Pty Limited 9,404,348 14.32%
    Citicorp Nominees Pty Limited 6,098,155 9.29%
    National Nominees Limited 2,009,236 3.06%
    BNP Paribas Noms Pty Ltd <Drp> 1,644,075 2.50%
    BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 792,246 1.21%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 451,702 0.69%
    HSBC Custody Nominees (Australia) Limited GSCO ECA 396,188 0.60%
    Australian Foundation Investment Company Limited 324,174 0.49%
    Netwealth Investments Limited <Wrap Services A/C> 305,565 0.47%
    BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 256,551 0.39%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 253,816 0.39%
    HSBC Custody Nominees (Australia) Limited <Euroclear Bank SA NV A/C> 176,502 0.27%
    Mr Christopher Graham Roberts 172,387 0.26%
    Custodial Services Limited <Beneficiaries Holding A/C> 152,756 0.23%
    HSBC Custody Nominees (Australia) Limited- A/C 2 133,789 0.20%
    BNP Paribas Nominees Pty Ltd ACF Clearstream 115,215 0.18%
    HSBC Custody Nominees (Australia) Limited- i 109,229 0.17%
    Cochlear Incentive Plan Pty Ltd <Cochlear Employee Share A/C> 101,003 0.15%
    BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient DRP> 61,520 0.09%

    Profile

    since

    Note